TFA Therapeutics (RAJAF) Net Margin (2020 - 2023)

TFA Therapeutics has reported Net Margin for 4 years, with the latest figure at 18.26% in Q4 2023.

• On a quarterly basis, Net Margin rose 361730.0% year-over-year to 18.26% in Q4 2023; TTM through Dec 2023 was 143.2%, a N/A change from a year earlier, with the FY2021 full-year figure at 0.0%, changed N/A from the prior year.
• Net Margin was 18.26% for Q4 2023 at TFA Therapeutics, up from 3599.04% in the prior quarter.
• The five-year high for Net Margin was 18.26% in Q4 2023, with the low at 4811.32% in Q4 2021.
• Average Net Margin over 4 years is 2100.52%, with a median of 1804.52% recorded in 2022.
• The sharpest annual moves came in 2021 and 2023: Net Margin plunged 480131 bps in 2021, then jumped 361730 bps in 2023.
• Over 4 years, Net Margin stood at 10.0% in 2020, then sank by 47999 bps to 4811.32% in 2021, then increased by 25 bps to 3599.04% in 2022, then surged by 101 bps to 18.26% in 2023.
• The last three Net Margin figures came in at 18.26% (Q4 2023), 3599.04% (Q4 2022), and 4811.32% (Q4 2021), per Business Quant data.